Dr. Reddy's Laboratories Full Year 2025 Earnings: In Line With Expectations

Simply Wall St · 06/10/2025 00:18

Dr. Reddy's Laboratories (NSE:DRREDDY) Full Year 2025 Results

Key Financial Results

  • Revenue: ₹325.5b (up 17% from FY 2024).
  • Net income: ₹56.5b (up 1.5% from FY 2024).
  • Profit margin: 17% (down from 20% in FY 2024). The decrease in margin was driven by higher expenses.
  • EPS: ₹67.88 (up from ₹66.93 in FY 2024).

DRREDDY Post-Clinical Trial Products

  • Pre-registration: 76.
revenue-and-expenses-breakdown
NSEI:DRREDDY Revenue and Expenses Breakdown June 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dr. Reddy's Laboratories Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

The primary driver behind last 12 months revenue was the Global Generics segment contributing a total revenue of ₹289.6b (89% of total revenue). The largest operating expense was General & Administrative costs, amounting to ₹92.9b (69% of total expenses). Explore how DRREDDY's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 5.7% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Dr. Reddy's Laboratories that you should be aware of.